ART1 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by targeted disruption of the ART1 gene in the UM-UC-3 human bladder carcinoma cell line. This genetically heterogeneous pool offers a robust loss?of?function model for investigating mono?ADP?ribosylation without the biases associated with clonal selection. The product provides a ready?to?use system for studying ART1?dependent signaling in a relevant cancer context.
The UM?UC?3 parental line originates from a male patient with transitional cell carcinoma of the bladder and is widely employed as a model for high?grade urothelial cancer. These cells exhibit dysregulated adhesion, survival, and motility??phenotypes that are central to tumor progression and metastasis. Their well?characterized growth properties and sensitivity to genetic manipulation make them an ideal host for interrogating the function of genes like ART1 in bladder malignancy.
ART1 (ADP?ribosyltransferase 1) catalyzes the transfer of a single ADP?ribose unit from NAD? to arginine residues on target proteins, a modification known as mono?ADP?ribosylation. This activity is stimulated by pro?inflammatory cytokines such as tumor necrosis factor (TNF) and interferon?gamma (IFN???), as well as by cellular stress. Downstream targets include integrins, histones, and components of the apoptotic machinery. By modifying integrins, ART1 can modulate cell?matrix adhesion, while ADP?ribosylation of apoptotic proteins influences cell death sensitivity. Within the broader signaling landscape, ART1 is functionally linked to the poly(ADP?ribose) polymerase (PARP) family, caspases, and integrin receptors, integrating ADP?ribosylation with apoptosis and integrin?mediated signaling pathways.
In bladder cancer, ART1?mediated mono?ADP?ribosylation may contribute to key malignant traits such as enhanced adhesion, migration, and resistance to apoptosis. Disruption of the ART1 gene in UM?UC?3 cells abolishes this enzymatic activity, potentially impairing integrin?dependent functions and rendering cells more susceptible to programmed death. This knockout model thus serves as a valuable platform to dissect the mechanistic role of ADP?ribosylation in bladder carcinoma and to identify molecular vulnerabilities that could be exploited for therapeutic intervention.
These polyclonal knockout cells are suited to a range of experimental workflows. Western blotting and ADP?ribosylation detection assays confirm loss of modification, while Annexin V?based apoptosis assays and flow cytometry quantify cell death and surface marker changes. Migration and invasion assays further assess metastatic potential. Together, these approaches facilitate investigations into ADP?ribosylation biology, apoptosis and migration mechanisms, and drug target validation in bladder cancer. For further details, contact Ascent Research.
